Claims for Patent: 10,668,042

Summary for Patent: 10,668,042

Title:	Methods of reducing the risk of cardiovascular events in a subject
Abstract:	In various embodiments, the present disclosure provides methods reducing the risk of cardiovascular events in a subject on statin therapy by administering to the subject a pharmaceutical composition comprising about 1 g to about 4 g of eicosapentaenoic acid ethyl ester or a derivative thereof.
Inventor(s):	Soni; Paresh (Mystic, CT)
Assignee:	Amarin Pharmaceuticals Ireland Limited (Dublin, IE)
Application Number:	16/391,128
Patent Claims:	1. A method of reducing risk of one or more of: myocardial infarction, stroke, cardiovascular death, unstable angina, coronary revascularization procedures and/or hospitalizations for unstable angina in a subject in need thereof, the method comprising administering daily to the subject 4 g of eicosapentaenoic acid ethyl ester (E-EPA) and a high intensity statin regimen, wherein the subject has elevated triglyceride levels and (1) established cardiovascular disease, or (2) diabetes and at least 2 additional risk factors for cardiovascular disease, wherein the high intensity statin regimen comprises about 40 mg to about 80 mg per day of atorvastatin or about 20 mg to about 40 mg per day of rosuvastatin. 2. The method of claim 1, wherein risk of occurrence of one or more components of a 3-point composite endpoint composed of cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke is reduced in the subject. 3. The method of claim 2, wherein risk of occurrence of one or more components of the 3-point composite endpoint composed of cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke is reduced by at least about 20% in the subject. 4. The method of claim 1, wherein risk of occurrence of one or more components of a 5-point composite endpoint composed of cardiovascular death, non-fatal stroke, non-fatal myocardial infarction, coronary revascularization, or unstable angina requiring hospitalization is reduced in the subject. 5. The method of claim 4, wherein risk of occurrence of one or more components of the 5-point composite endpoint composed of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, coronary revascularization, or unstable angina requiring hospitalization is reduced by at least about 20% in the subject. 6. The method of claim 1, wherein the subject is less than about 65 years of age. 7. The method of claim 1, wherein the subject has a high sensitivity reactive protein (hsCRP) level of 2 mg/L or less. 8. The method of claim 1, wherein the subject has a fasting baseline triglyceride level of at least about 200 mg/dL and a fasting baseline high density lipoprotein-C (HDL-C) level of about 35 mg/dL or less. 9. The method of claim 1, wherein the subject has a fasting baseline triglyceride level of about 135 mg/dL to about 500 mg/dL. 10. The method of claim 1, wherein the administering occurs for at least about 2 years.